<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87248">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01774851</url>
  </required_header>
  <id_info>
    <org_study_id>MM-111-13-02-04</org_study_id>
    <nct_id>NCT01774851</nct_id>
  </id_info>
  <brief_title>A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach</brief_title>
  <official_title>Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel With Trastuzumab in Patients With HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merrimack Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merrimack Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether the combination of MM-111 plus paclitaxel and trastuzumab is more
      effective than paclitaxel and trastuzumab alone
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, open Label, Phase 2 Study of MM-111 and Paclitaxel withTrastuzumab in
      Patients with HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE)
      Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy.
      Approximately 120 patients will be randomized in a 1:1 ratio between the experimental and
      comparator arms.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>30 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>HER-2 Gene Amplification</condition>
  <condition>Esophagus Cancer</condition>
  <condition>Gastroesophageal Junction Cancer</condition>
  <condition>Stomach Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MM-111 + Paclitaxel + Trastuzumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1b</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel + Trastuzumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MM-111</intervention_name>
    <description>MM-111 (IV)</description>
    <arm_group_label>Arm 1a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel (IV)</description>
    <arm_group_label>Arm 1a</arm_group_label>
    <arm_group_label>Arm 1b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Trastuzumab (IV)</description>
    <arm_group_label>Arm 1a</arm_group_label>
    <arm_group_label>Arm 1b</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have documentation of histologically or cytologically confirmed
             metastatic or locally advanced adenocarcinoma of the distal esophagus, GE junction or
             stomach

          -  Patients must have documentation of histologically or cytologically confirmed HER2
             expression

          -  Patients must be ≥18 years of age

          -  Patients must have ECOG PS of 0, 1, or 2

          -  Patients must have adequate hematologic status, renal and hepatic function

        Exclusion Criteria:

          -  Patients with known hypersensitivity to any of the components of MM-111

          -  Patients with a known history of hypersensitivity to paclitaxel or other drugs
             formulated in Cremophor® EL

          -  Patients with a known history of hypersensitivity to trastuzumab or any of its
             components (group 1 patients only)

          -  Patients with an active infection or with an unexplained fever &gt;38.5°C
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Akos Czibere, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Merrimack Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sasha Frye</last_name>
    <phone>617-441-7667</phone>
    <email>sfrye@merrimackpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan Leahy</last_name>
      <phone>215-214-1472</phone>
      <email>joan.bloch@fccc.edu</email>
    </contact>
    <investigator>
      <last_name>Crystal Denlinger, D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 4, 2014</lastchanged_date>
  <firstreceived_date>January 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER-2 Gene Amplification</keyword>
  <keyword>Esophagus Cancer</keyword>
  <keyword>Gastroesophageal Junction Cancer</keyword>
  <keyword>Stomach Cancer</keyword>
  <keyword>Her2 Positive</keyword>
  <keyword>Her2+</keyword>
  <keyword>Esophageal Cancer</keyword>
  <keyword>Metastatic</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
